# Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma

> **NCT00617799** · — · COMPLETED · sponsor: **University of Nebraska** · enrollment: 15 (actual)

## Conditions studied

- Kidney Cancer
- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** aldesleukin
- **GENETIC:** gene expression analysis
- **GENETIC:** mutation analysis
- **OTHER:** flow cytometry

## Key facts

- **NCT ID:** NCT00617799
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10-02
- **Primary completion:** 2009-02-18
- **Final completion:** 2010-04-16
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00617799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00617799, "Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00617799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*